Audio Coursesby JellypodLesson 09 of 15
Overview
This episode explores how stroke management has evolved from individual interventions to a complex systems problem. Jeremy and Hamish break down integrated stroke care pathways, spotlight tech-driven solutions, and examine where the system still fails patients.
Jeremy: Welcome back to the TIME Podcast, I’m Hamish.
Hamish: And I’m Jermey. The TIME Podcast is where we take a step back from day-to-day clinical firefighting and look at how evidence, systems and decision-making actually intersect in acute care.
Hamish: Today we’re talking about acute stroke — not because there’s a single new trial everyone needs to memorise, but because the ground has shifted under how stroke care is organised.
Jeremy: Over the past few years, evidence has expanded faster than many of the systems designed to deliver it. That mismatch is now shaping who gets treated, who doesn’t, and how much pressure gets pushed back onto individual clinicians.
Hamish: So this isn’t a therapy-by-therapy update.
Jeremy: It’s a conversation about how modern stroke care now depends as much on pathways, governance and system design as it does on clinical judgement.
Hamish: If you work in emergency medicine, retrieval or critical care, some of this will feel very familiar.
Jeremy: And some of it may feel uncomfortable — particularly if you’ve ever known what should happen for a patient, but couldn’t quite make the system do it.
Hamish: This is the TIME Podcast. Let’s get into it.
Hamish: If you take a step back from individual trials, stroke care now feels different in a way that’s hard to quantify but immediately recognisable if you’re working clinically.
Jeremy: It’s heavier.
Hamish: Exactly. Not just busier or faster — heavier. Decisions that used to feel binary now feel conditional, and that conditionality has consequences.
Jeremy: I think what’s changed is that uncertainty used to protect us. Large core, late window, unclear benefit — those were legitimate stopping points. They absorbed significant system risk.
Hamish: And that protection has eroded.
Jeremy: Yes. The evidence base has expanded to the point where “nothing to offer” is much harder to defend — but the systems expected to deliver that evidence haven’t expanded at the same pace.
Hamish: Which means the risk hasn’t disappeared. It’s just moved.
Jeremy: And often moved onto the clinician at the front door. The ED doctor deciding whether to activate a stroke pathway at two in the morning. The retrieval consultant deciding whether this is “worth the flight”. The ICU registrar inheriting a patient who maybe could have been treated earlier.
Hamish: That’s a big shift. Stroke outcomes are no longer just a function of biology and time — they’re a function of how confidently a system commits early.
Jeremy: But here’s the uncomfortable part. Many systems say they want early activation and aggressive pathways — but they still punish over-activation.
Hamish: How so?
Jeremy: Angio suites get saturated. Retrieval teams get stretched. Smaller hospitals get labelled as “overcalling”. And none of that is captured in outcome metrics.
Hamish: So clinicians adapt.
Jeremy: Exactly. They hedge. They wait for more certainty. They downplay borderline cases. Not because they don’t care — but because they’re reading the system signals correctly.
Hamish: That creates a quiet moral tension. Because the evidence is telling you a benefit might exist, but the system is telling you capacity is finite.
Jeremy: And that tension shows up as cognitive load. Stroke becomes mentally expensive. Every decision feels like it has downstream consequences you’re personally responsible for.
Hamish: Which is why stroke now feels less like a protocolised clinical problem and more like an organisational stress test.
efbba67d: And it’s worth saying out loud: in many places, stroke outcomes are now being shaped more by workflow and governance than by the treatments themselves.
Hamish: That’s the lens we’re using for this episode. Because once you see stroke this way, the individual innovations — thrombectomy, tenecteplase, prehospital models — look very different.
Jeremy: They stop being “advances” in isolation and start being demands placed on the system.
Hamish: If there’s one area where the evidence has most obviously forced a rethink, it’s thrombectomy.
Jeremy: And not just clinically — philosophically.
Hamish: For a long time, a large infarct core was treated as a hard stop. Low ASPECTS meant futility, and that gave systems a clean, defensible boundary.
Jeremy: Which mattered. Because boundaries don’t just guide care — they distribute responsibility.
Hamish: SELECT2 dismantled that boundary. Patients with large established infarcts, treated up to 24 hours, still derived meaningful functional benefit.
Jeremy: And crucially, that benefit wasn’t just a statistical artefact at 90 days. One-year outcomes showed sustained gains in independence and living situation.
Hamish: ANGEL-ASPECT and TENSION reinforced that across very different health systems. And then we get the JAMA trial showing non-contrast CT alone can identify patients who still benefit.
Jeremy: From a clinical perspective, that’s liberating.
Hamish: But from a systems perspective, it’s destabilising.
Jeremy: Exactly. Because we’ve removed a clear exclusion criterion without replacing it with an equally clear inclusion rule.
Hamish: So instead of “this patient is out,” we’re left with “this patient might benefit.”
Jeremy: Which sounds reasonable — until you’re the ED consultant at 3 a.m. with a borderline large-core stroke, limited imaging, and a retrieval service already under strain.
Hamish: Let’s make that real. A patient presents late, ASPECTS maybe 4 or 5 depending on who’s looking, dense hemiplegia, premorbidly independent. CTA shows a proximal occlusion.
Jeremy: Neurology is cautiously optimistic. The angio centre says, “Send if you think there’s upside.” Retrieval asks how confident you are.
Hamish: And that’s the trap. Confidence becomes the currency — not eligibility.
Jeremy: Which quietly shifts liability. The system hasn’t said “yes” or “no” — it’s said, “You decide.”
Hamish: I’d argue that’s unavoidable. These are nuanced decisions. No trial can replace judgment.
Jeremy: I don’t disagree — but I think we underestimate the downstream effects. Expanded eligibility increases activation, not just treatment. Angio suites fill. Retrieval flights multiply. ICUs inherit more complex patients with uncertain trajectories.
Hamish: But isn’t that the price of progress?
Jeremy: Only if the system absorbs it deliberately. What I worry about is unacknowledged saturation — where expanded thrombectomy quietly displaces other care, or pushes teams into riskier heuristics.
Hamish: Such as?
Jeremy: Hedging again. Delaying referral to see if deficits evolve. Over-interpreting imaging pessimistically. Not because clinicians don’t believe the evidence, but because capacity is finite and the consequences of being wrong are asymmetric.
Hamish: That’s uncomfortable, but probably true.
Jeremy: And it raises a hard question: have we expanded thrombectomy eligibility without equally expanding governance around who owns those decisions?
Hamish: Because right now, many systems have broader evidence, but the same old pathways.
Jeremy: Exactly. And that means the moral weight of “missing benefit” lands on individuals, while the system retains plausible deniability.
Hamish: So while I think expanded thrombectomy is absolutely the right direction clinically —
Jeremy: —I think it’s dangerous to pretend it’s a purely clinical advance. It’s a systems stressor.
Hamish: And unless leadership explicitly redistributes risk — through clear referral criteria, protected capacity, and shared ownership — clinicians will adapt in ways the trials never modelled.
Jeremy: Which is why this isn’t a debate about whether thrombectomy works.
Hamish: It’s a debate about whether our systems are honest about what it costs.
Hamish: If thrombectomy has forced systems to confront complexity, tenecteplase has done almost the opposite. It’s simplified things — at least on the surface.
Jeremy: And that’s precisely why it deserves scrutiny.
Hamish: Clinically, the evidence is reassuring. TASTE-A showed higher early reperfusion compared with alteplase, without an increase in symptomatic intracranial haemorrhage. ORIGINAL confirmed non-inferiority at ninety days using the now-standard 0.25 mg/kg dose.
Jeremy: And meta-analyses settled the dosing question. Higher doses increased bleeding risk. Practice stabilised.
Hamish: Operationally, it’s been transformative. A single bolus instead of an infusion. Easier transfers. Cleaner handovers. Less equipment, fewer failure points.
Jeremy: All of which is genuinely helpful. But simplicity isn’t neutral — it changes behaviour.
Hamish: In what way?
Jeremy: Tenecteplase reduces friction at exactly the moment when systems used to slow clinicians down. Alteplase’s complexity forced pauses — weight checks, infusion pumps, double-checks. Those pauses weren’t always efficient, but they acted as cognitive speed bumps.
Hamish: You’re suggesting those speed bumps had protective value.
Jeremy: Yes. With tenecteplase, the pathway becomes cleaner and faster — but also easier to trigger reflexively.
Hamish: That sounds like a good thing for stroke.
Jeremy: Up to a point. The risk is false reassurance. A sense that, because administration is easy, the decision itself is easy.
Hamish: But eligibility criteria haven’t changed.
Jeremy: On paper, no. In practice, cognitive thresholds drift. When something is simple to do, systems tend to tolerate more uncertainty around whether to do it.
Hamish: So borderline cases creep in.
Jeremy: Exactly. Mild deficits. Wake-up strokes with limited history. Uncertain onset times. Tenecteplase doesn’t cause those decisions — but it lowers the psychological cost of making them.
Hamish: I’d argue that’s still a net positive. More patients are getting timely therapy.
Jeremy: Possibly. But only if governance keeps pace. Because when adverse events occur, the question becomes: who made the decision?
Hamish: The clinician who pushed the drug?
Jeremy: Or the system that made the push effortless but left decision thresholds vague?
Hamish: That’s a fair challenge.
Jeremy: This matters particularly in smaller centres and prehospital environments, where support structures are thinner. Tenecteplase shifts cognitive load upstream — to the moment of decision — without always reinforcing decision support.
Hamish: So the risk isn’t the drug.
Jeremy: No. The risk is protocol drift. Over time, “easy” becomes “routine,” and “routine” becomes “expected.”
Hamish: Which makes it harder to say no.
Jeremy: Exactly. And that’s where simplicity can quietly increase harm — not through pharmacology, but through behaviour.
Hamish: So the real lesson from tenecteplase isn’t just about efficiency.
Jeremy: It’s about matching operational simplicity with equally clear governance. Explicit eligibility. Clear escalation pathways. And protection for clinicians who decide not to treat.
Hamish: Because otherwise, simplicity just moves risk around.
Jeremy: And stroke systems are already carrying enough invisible risk as it is.
Hamish: When people talk about systems-level change in stroke, they often point to visible innovations — Mobile Stroke Units, hybrid angio suites, direct-to-angiography pathways.
Jeremy: Those are the easy parts to see. The harder parts are the behaviours those systems produce under pressure.
Hamish: Modern stroke care assumes that delay itself is pathological. Every extra handover, every duplicated assessment, every unclear referral threshold is treated as a potential brain injury.
Jeremy: And that assumption has quietly rewired how stroke networks behave. Activation is no longer conservative — it’s permissive.
Hamish: Which makes sense. With expanded thrombectomy eligibility and longer treatment windows, under-triage is now seen as the bigger risk.
Jeremy: But permissive activation has consequences that aren’t evenly distributed.
Hamish: Explain that.
Jeremy: Angio suites saturate first. Then, retrieval services. Then ICUs. The pressure propagates outward from tertiary centres to the rest of the network.
Hamish: So the system absorbs the load — until it doesn’t.
Jeremy: Exactly. And when it doesn’t, the failure mode is rarely dramatic. There’s no collapse. No announcement. Things just quietly slow down.
Hamish: Let’s give a concrete example.
Jeremy: A regional ED activates a stroke pathway for a late-window, large-core patient. It’s borderline but defensible. The angio centre agrees to accept. Retrieval is delayed because aircraft are committed elsewhere.
Hamish: By the time the patient arrives, the angio suite is backed up. The case is technically still eligible — but the physiology has drifted. Blood pressure unstable. Consciousness reduced.
Jeremy: The procedure is deferred. Not because anyone made a wrong decision, but because the system couldn’t move fast enough to honour the original one.
Hamish: And from the outside, that looks like a patient who “wasn’t a candidate.”
Jeremy: But from the inside, it’s a failure of the pathway.
Hamish: This is where ownership becomes critical. Who owns that failure?
Jeremy: Often, no one. The ED activated appropriately. Retrieval did their best. The angio team responded when they could.
Hamish: So the system shrugs.
Jeremy: And that’s dangerous. Because when failures are ownerless, they become invisible — and invisible failures don’t get fixed.
Hamish: High-performing stroke systems handle this differently.
Jeremy: They make ownership explicit. Clear stroke leads. Defined escalation thresholds. Agreed tolerances for over-activation. And critically, feedback loops.
Hamish: Feedback not just on outcomes, but on process.
Jeremy: Exactly. Why was this patient delayed? Where did the time go? Was this a capacity issue, a triage issue, or a governance issue?
Hamish: Without that, clinicians adapt quietly.
Jeremy: They learn when not to activate. Which cases will “go nowhere.” Which referrals will bounce. And those heuristics become self-reinforcing.
Hamish: That’s how inequity creeps in.
Jeremy: Yes. Rural centres, after-hours cases, borderline presentations — these patients are disproportionately affected, even though the evidence says they might benefit.
Hamish: So the system says it’s permissive, but behaviour becomes selective.
Jeremy: Because saturation isn’t free. Someone always pays the price.
Hamish: Which brings us back to leadership.
Jeremy: Stroke systems now require leaders to decide where risk sits. Do we protect angio capacity? Retrieval sustainability? Or individual clinicians from moral overload?
Hamish: Those are trade-offs. There’s no clean answer.
Jeremy: But pretending they don’t exist is the worst option.
Hamish: Because when systems refuse to name trade-offs, clinicians end up absorbing them — silently.
Jeremy: And that’s where modern stroke care either succeeds or fails.
Hamish: If ischaemic stroke has been about expanding possibility, intracerebral haemorrhage has felt like a story of repeated disappointment.
Jeremy: Years of biologically plausible ideas that never quite translated into functional benefit.
Hamish: Haemostatic agents, surgical timing, neuroprotection — none of it reliably moved the needle.
Jeremy: Which is why INTERACT3 is so confronting. Because it didn’t succeed in discovering something new. It succeeded by enforcing discipline.
Hamish: At its core, INTERACT3 reframed ICH as a problem of secondary injury — and treated physiology as something that had to be controlled early, consistently, and collectively.
Jeremy: Blood pressure is the obvious example. We’ve known for years that elevated systolic pressure correlates with haematoma expansion and worse outcomes. INTERACT2 showed that early lowering to around 140 mmHg was safe. ATACH-II showed that aggressive, poorly titrated reduction could cause harm.
Hamish: INTERACT3 didn’t split the difference — it changed the question. Instead of asking “how low?” it asked “how reliably?”
Jeremy: Rapid reduction below 140, yes — but more importantly, maintenance. Avoiding drift, rebound, and variability across the first critical hours.
Hamish: And that’s where this becomes a systems issue, not a pharmacological one.
Jeremy: Because maintaining blood pressure targets requires handover discipline, shared ownership, and clarity about who’s responsible at each transition — ED to CT, CT to ICU, ICU to overnight cover.
Hamish: The same applies to anticoagulation reversal, glucose control, temperature management, and neurological observation. None of these are novel. What’s novel is insisting they all happen, every time.
Jeremy: And that insistence exposes system weaknesses.
Hamish: Such as?
Jeremy: Fragmentation. ED starts the infusion, ICU assumes it’s sorted. ICU adjusts sedation, BP drifts. Overnight staffing is thinner, targets loosen. No one intends harm — but discipline decays.
Hamish: INTERACT3 worked because the bundle was treated as a single intervention, not a menu.
Jeremy: Exactly. And that’s where real-world implementation struggles. Bundles require cultural buy-in, not just protocols.
Hamish: I’d argue this is actually encouraging. It suggests ICH outcomes are modifiable without waiting for the next miracle drug.
Jeremy: I agree — but with a caveat. Bundled care scales unevenly. Well-resourced centres can sustain discipline. Smaller hospitals, after-hours teams, and stretched ICUs struggle.
Hamish: So the very model that improves outcomes can widen gaps.
Jeremy: Yes. INTERACT3 assumes a level of staffing stability, monitoring capacity, and governance oversight that isn’t universal.
Hamish: Which brings us back to leadership.
Jeremy: Precisely. If we adopt INTERACT3 principles without resourcing the discipline they require, we risk turning “guideline-aligned care” into another aspirational standard clinicians feel they’re failing.
Hamish: So the lesson from INTERACT3 isn’t just “do this.”
Jeremy: It’s “decide who owns this, and fund it accordingly.”
Hamish: Because discipline without support is just pressure.
Jeremy: And pressure without ownership is how systems break quietly.
Hamish: All of these changes sit within the framework of Australia and New Zealand’s Living Clinical Guidelines for Stroke Management.
Jeremy: And on paper, that sounds like an unqualified good.
Hamish: Guidelines that update in near real time. Rapid incorporation of new evidence. Less lag between trial publication and practice.
Jeremy: But living guidelines expose a tension that’s easy to miss if you only think clinically. Evidence can now move continuously — systems can’t.
Hamish: Hospitals still operate on discrete protocols, fixed order sets, credentialing processes, and governance cycles that were designed for static guidelines.
Jeremy: Which means every guideline update creates a gap. Not between evidence and ignorance — but between evidence and implementation.
Hamish: You see it with thrombectomy eligibility. The guideline expands. Referral language softens. But local pathways still reflect older assumptions.
Jeremy: Or tenecteplase becomes first-line in the guideline, but pharmacy stocking, ambulance protocols, and education lag behind.
Hamish: From a clinician’s perspective, that creates ambiguity.
Jeremy: And ambiguity isn’t neutral. It shifts risk.
Hamish: How so?
Jeremy: When guidelines change faster than systems, clinicians are left to decide how much weight to give the “living” recommendation versus the “local” pathway. That’s a governance problem disguised as clinical judgement.
Hamish: So the person at the bedside is effectively arbitrating between two authorities.
Jeremy: Exactly. And whichever way they choose, they’re exposed. Follow the guideline and deviate from local policy, or follow local policy and risk under-treating.
Hamish: That’s an uncomfortable place to practise.
Jeremy: It’s also unevenly distributed. Large tertiary centres often have the governance machinery to update pathways quickly. Smaller hospitals don’t.
Hamish: So the same guideline produces different realities depending on postcode.
Jeremy: Which is the equity issue we don’t talk about enough. Living guidelines can inadvertently widen gaps between well-resourced systems and those perpetually catching up.
Hamish: I think many leaders underestimate that.
Jeremy: Because from a distance, it looks like progress. But on the ground, it can feel like moving goalposts without new boots.
Hamish: There’s also a cultural issue.
Jeremy: Yes. Living guidelines assume continuous engagement. But clinicians weren’t trained for that. Most of us were socialised to think of guidelines as periodic reference points, not dynamic documents.
Hamish: So without deliberate support, guideline literacy becomes another hidden cognitive load.
Jeremy: And when people are overloaded, they default to habit.
Hamish: Which brings us back to system behaviour.
Jeremy: Living guidelines only improve care if systems are designed to translate them — with clear communication, updated pathways, education, and explicit statements about what has changed and what hasn’t.
Hamish: Otherwise, they risk becoming aspirational documents that expose gaps without fixing them.
Jeremy: Or worse — they create a quiet moral injury, where clinicians feel they’re practising below standard because the system can’t keep up.
Hamish: So the real challenge of living guidelines isn’t evidence synthesis.
Jeremy: It’s organisational honesty. Acknowledging what you can deliver now, what you’re working toward, and where the limits are.
Hamish: Because pretending a system is “living” when it’s actually static just pushes pressure downstream.
Jeremy: And in stroke care, downstream pressure translates directly into lost opportunity.
Hamish: If we step back from the individual components — thrombectomy, thrombolysis, blood pressure targets, living guidelines — a pattern becomes hard to ignore.
Jeremy: Stroke care is no longer limited by what we know how to do.
Hamish: We know thrombectomy benefits extend further than we once believed. We know thrombolysis can be delivered more simply. We know that disciplined physiological control improves outcomes in haemorrhage.
Jeremy: What’s limiting now is whether systems can reliably deliver those interventions under real-world conditions.
Hamish: Modern stroke care assumes early recognition, rapid imaging, permissive activation, sustained physiological discipline, and seamless handover across teams and institutions.
Jeremy: Those assumptions are baked into the evidence — but they’re not evenly distributed across health systems.
Hamish: And that’s the uncomfortable truth. Two patients with the same stroke, the same biology, the same potential for benefit can have very different outcomes — not because of chance, but because of pathway design.
Jeremy: Which forces a reframing of responsibility. When a patient doesn’t receive contemporary stroke care, the question is no longer just “Was this clinically appropriate?”
Hamish: It’s “Did the system make it possible?”
Jeremy: And increasingly, the answer sits with leadership rather than individuals.
Hamish: That doesn’t mean clinicians don’t matter. They matter enormously.
Jeremy: But they’re now operating inside systems where decisions are shaped by capacity, governance, and tolerance for risk — often in ways that are invisible until something goes wrong.
Hamish: This is where many systems struggle. They celebrate innovation but avoid the harder work of redistributing risk, naming trade-offs, and owning failure modes.
Jeremy: And when that happens, clinicians quietly absorb the pressure. They hedge. They adapt. They ration without saying so.
Hamish: Which is why the most important stroke intervention in 2025 may not be a device, a drug, or a protocol.
Jeremy: It may be organisational honesty.
Hamish: Honesty about what your system can deliver today. What it can’t. And who carries the consequences when demand exceeds capacity?
Jeremy: Because stroke care has crossed a threshold. The system is no longer just the context in which care happens.
Hamish: The system is the treatment.
Jeremy: And until we design systems with the same rigour we apply to trials, some patients will continue to miss benefit — quietly, unevenly, and without anyone explicitly deciding that they should.
Hamish: That’s not a failure of evidence.
Jeremy: It’s a failure of design.
Hamish: And it’s the challenge this generation of clinicians and leaders now inherits.
Hamish: So let’s bring this out of theory and into Monday morning.
Jeremy: Because the risk with conversations like this is that everyone agrees in principle, and nothing changes in practice.
Hamish: Imagine you’re back in your service next week. You’ve absorbed the evidence. You know thrombectomy eligibility has expanded. You know INTERACT3 demands discipline. You know the guidelines are living.
Jeremy: The first real question isn’t clinical. It’s structural. Do you actually know who owns stroke activation decisions in your system?
Hamish: Not who makes them, but who owns them when capacity is exceeded.
Jeremy: If your ED activates three borderline thrombectomy cases overnight and the angio suite backs up, is that success or failure?
Hamish: And who decides?
Jeremy: If retrieval says “not tonight,” is that a clinical decision, a capacity decision, or a funding decision?
Hamish: Because those are very different things — but they’re often treated as interchangeable.
Jeremy: Here’s another uncomfortable one. If your service says it follows the living stroke guidelines, can it actually deliver them at 2 a.m. on a Sunday?
Hamish: And if it can’t, is that explicitly acknowledged — or quietly ignored?
Jeremy: Because pretending a pathway exists when it only works in business hours is not neutrality. It’s rationing by default.
Hamish: For clinicians listening, there’s a parallel question.
Jeremy: Are you carrying system risk without realising it?
Hamish: Are you the one deciding not to activate because you know how hard it is to make things happen downstream?
Jeremy: And if so, have you ever named that — or have you absorbed it as “clinical judgement”?
Hamish: For leaders, the challenge is sharper.
Jeremy: Have you explicitly decided where over-activation is acceptable, and where it isn’t?
Hamish: Have you defined how much inefficiency you’re willing to tolerate to avoid missing benefit?
Jeremy: Or are you relying on clinicians to self-regulate in ways that keep the system afloat but the trade-offs invisible?
Hamish: There’s no perfect answer to any of this.
Jeremy: But there is a wrong approach — and that’s acting as if these tensions don’t exist.
Hamish: Because if they’re not owned at a system level, they will be managed — imperfectly — at the bedside.
Jeremy: And that’s where modern stroke care quietly breaks.
Hamish: If this conversation has felt uncomfortable at times, that’s probably appropriate.
Jeremy: Because the evidence has moved faster than many of our systems — and pretending otherwise doesn’t protect patients or clinicians.
Hamish: Stroke care now asks different questions of us. Not just about what we know, but about what we’re prepared to own.
Jeremy: And whether we’re willing to name the trade-offs that are already being made — often quietly, often by individuals rather than systems.
Hamish: This podcast is part of a broader conversation hosted by Clintix — about how complex evidence actually gets translated into real clinical environments.
Jeremy: Not ideally. Not on paper. But under pressure, at night, with finite resources.
Hamish: Thanks for listening to the TIME Podcast.
Jeremy: We’ll leave it there. Bye!
